Medicus Pharma (NASDAQ:MDCX – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They ...

Bansal has driven a sharp rebound in Boral’s performance during his time, and will move onto the board of Stokes’ SGH group ...

Boral chief executive Vik Bansal will quit the building materials supplier in early 2026 after just three years in the top job, with investors in parent company SGH cautious about the succession ...

The businessman will leave the building materials giant he has run since 2022 and become a director of the Stokes family ...

Fintel reports that on June 30, 2025, D. Boral Capital downgraded their outlook for CorMedix (NasdaqGM:CRMD) from Buy to Hold ...

ASX edged higher as Wall Street hit fresh highs, gold climbed on rate-cut hopes, while SGH and HMC stumbled on leadership ...

Fintel reports that on June 23, 2025, D. Boral Capital upgraded their outlook for CERo Therapeutics Holdings (NasdaqCM:CERO) ...

LONDON, Ontario, June 20, 2025("Aduro" or the "Company") (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company ...

Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company ...

Boral’s ROIC has risen every year from 2.4% in 2020 to 7.1% in 2023, and we anticipate it to exceed our assumed 7.9% WACC from fiscal 2026. However, we don’t think this will be sufficiently so ...

Boral director Rob Sindel is taking on Kerry Stokes. Seven declared the offer final, so the choice for investors is binary. They can’t negotiate for a higher price.

Australia's Boral on Tuesday recommended investors reject its largest shareholder Seven Group Holdings' A$1.9 billion ($1.25 billion) offer for the company claiming it undervalues the building ...